344 related articles for article (PubMed ID: 18207611)
1. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Baek RC; Kasperzyk JL; Platt FM; Seyfried TN
Neurochem Int; 2008 May; 52(6):1125-33. PubMed ID: 18207611
[TBL] [Abstract][Full Text] [Related]
2. N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
Kasperzyk JL; El-Abbadi MM; Hauser EC; D'Azzo A; Platt FM; Seyfried TN
J Neurochem; 2004 May; 89(3):645-53. PubMed ID: 15086521
[TBL] [Abstract][Full Text] [Related]
3. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
Andersson U; Smith D; Jeyakumar M; Butters TD; Borja MC; Dwek RA; Platt FM
Neurobiol Dis; 2004 Aug; 16(3):506-15. PubMed ID: 15262262
[TBL] [Abstract][Full Text] [Related]
4. Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
Denny CA; Heinecke KA; Kim YP; Baek RC; Loh KS; Butters TD; Bronson RT; Platt FM; Seyfried TN
J Neurochem; 2010 Jun; 113(6):1525-35. PubMed ID: 20374428
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice.
Arthur JR; Lee JP; Snyder EY; Seyfried TN
Neurochem Res; 2012 Jun; 37(6):1335-43. PubMed ID: 22367451
[TBL] [Abstract][Full Text] [Related]
6. Specific induction of macrophage inflammatory protein 1-alpha in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates.
Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Kuwahara J; Yamanaka S; Itoh K
J Neurochem; 2005 Mar; 92(6):1497-507. PubMed ID: 15748167
[TBL] [Abstract][Full Text] [Related]
7. Metabolic correction in microglia derived from Sandhoff disease model mice.
Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Itoh K
J Neurochem; 2005 Sep; 94(6):1631-8. PubMed ID: 16092933
[TBL] [Abstract][Full Text] [Related]
8. Influence of caloric restriction on motor behavior, longevity, and brain lipid composition in Sandhoff disease mice.
Denny CA; Kasperzyk JL; Gorham KN; Bronson RT; Seyfried TN
J Neurosci Res; 2006 May; 83(6):1028-38. PubMed ID: 16521125
[TBL] [Abstract][Full Text] [Related]
9. Reversion of the biochemical defects in murine embryonic Sandhoff neurons using a bicistronic lentiviral vector encoding hexosaminidase alpha and beta.
Arfi A; Zisling R; Richard E; Batista L; Poenaru L; Futerman AH; Caillaud C
J Neurochem; 2006 Mar; 96(6):1572-9. PubMed ID: 16441513
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of abnormal growth in astrocytes derived from a mouse model of GM2 gangliosidosis.
Kawashima N; Tsuji D; Okuda T; Itoh K; Nakayama K
J Neurochem; 2009 Nov; 111(4):1031-41. PubMed ID: 19765188
[TBL] [Abstract][Full Text] [Related]
11. Ethylenedioxy-PIP2 oxalate reduces ganglioside storage in juvenile Sandhoff disease mice.
Arthur JR; Wilson MW; Larsen SD; Rockwell HE; Shayman JA; Seyfried TN
Neurochem Res; 2013 Apr; 38(4):866-75. PubMed ID: 23417430
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
Pelled D; Lloyd-Evans E; Riebeling C; Jeyakumar M; Platt FM; Futerman AH
J Biol Chem; 2003 Aug; 278(32):29496-501. PubMed ID: 12756243
[TBL] [Abstract][Full Text] [Related]
13. N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.
Ranes MK; El-Abbadi M; Manfredi MG; Mukherjee P; Platt FM; Seyfried TN
Br J Cancer; 2001 Apr; 84(8):1107-14. PubMed ID: 11308262
[TBL] [Abstract][Full Text] [Related]
14. NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
Jeyakumar M; Smith DA; Williams IM; Borja MC; Neville DC; Butters TD; Dwek RA; Platt FM
Ann Neurol; 2004 Nov; 56(5):642-9. PubMed ID: 15505823
[TBL] [Abstract][Full Text] [Related]
15. Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice.
Itakura T; Kuroki A; Ishibashi Y; Tsuji D; Kawashita E; Higashine Y; Sakuraba H; Yamanaka S; Itoh K
Biol Pharm Bull; 2006 Aug; 29(8):1564-9. PubMed ID: 16880605
[TBL] [Abstract][Full Text] [Related]
16. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
Jeyakumar M; Butters TD; Cortina-Borja M; Hunnam V; Proia RL; Perry VH; Dwek RA; Platt FM
Proc Natl Acad Sci U S A; 1999 May; 96(11):6388-93. PubMed ID: 10339597
[TBL] [Abstract][Full Text] [Related]
17. Intravenous administration of scAAV9-Hexb normalizes lifespan and prevents pathology in Sandhoff disease mice.
Niemir N; Rouvière L; Besse A; Vanier MT; Dmytrus J; Marais T; Astord S; Puech JP; Panasyuk G; Cooper JD; Barkats M; Caillaud C
Hum Mol Genet; 2018 Mar; 27(6):954-968. PubMed ID: 29325092
[TBL] [Abstract][Full Text] [Related]
18. Phospholipid synthesis is decreased in neuronal tissue in a mouse model of Sandhoff disease.
Buccoliero R; Bodennec J; Van Echten-Deckert G; Sandhoff K; Futerman AH
J Neurochem; 2004 Jul; 90(1):80-8. PubMed ID: 15198669
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease.
Baek RC; Martin DR; Cox NR; Seyfried TN
Lipids; 2009 Mar; 44(3):197-205. PubMed ID: 19034545
[TBL] [Abstract][Full Text] [Related]
20. beta-hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration.
Kyrkanides S; Miller JH; Brouxhon SM; Olschowka JA; Federoff HJ
Brain Res Mol Brain Res; 2005 Feb; 133(2):286-98. PubMed ID: 15710246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
